TICKERNERD
Menu
GUTSGUTSHealthcare · Biotechnology

GUTS Stock Forecast: Fractyl Health, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$4.88

The 7 Wall Street analysts covering Fractyl Health, Inc. hold a median 12-month price target of $5.1 — +4.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 3 Oct 2026 — in the lower half.

Market cap
$64.8M
Ticker Nerd rank
30 / 100
Median analyst target
$5.10
Analysts covering
7
Revenue$0.0
Operating income−$19.1M
Net income−$25.5M
Free cash flow−$15.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

GUTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fractyl Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
80
Accruals
75
Growth
63
Revisions
59
Issuance
39
Momentum
17
Value
14
Volatility
13
Quality
8

Size (80): Smaller than most of the companies we track.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GUTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GUTS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $2.00Median $5.10High $8.00

The green dot is the last close — the median target sits +4.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 July 2026Craig-HallumInitiatesBuy$4.00
4 June 2026HC Wainwright & Co.ReiteratesBuy—
24 Apr 2026HC Wainwright & Co.ReiteratesBuy—
26 Mar 2026Canaccord GenuityMaintainsBuy—
30 Jan 2026Morgan StanleyDowngradeEqual-Weight—
2 Dec 2025HC Wainwright & Co.ReiteratesBuy—
21 Nov 2025Canaccord GenuityMaintainsBuy—
26 Sept 2025HC Wainwright & Co.MaintainsBuy—
15 Sept 2025HC Wainwright & Co.InitiatesBuy—
28 Aug 2025Ladenburg ThalmannInitiatesBuy—
14 Aug 2025Canaccord GenuityMaintainsBuy—
15 Apr 2025Canaccord GenuityInitiatesBuy—
3 Feb 2025Morgan StanleyMaintainsOverweight—
28 Feb 2024Evercore ISI GroupInitiatesOutperform—
27 Feb 2024Morgan StanleyInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GUTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GUTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Fractyl Health, Inc. (GUTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
−39.1×

Cheaper than 99% of US stocks

EV / EBITDA
−0.9×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1490.3%

Higher than 1% of US stocks

Return on assets
−74.6%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fractyl Health, Inc. (GUTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fractyl Health, Inc. has a market value of $64.8M and an enterprise value of $78.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.7M.

  • Diluted earnings per share, trailing twelve months: $−1.10.

  • Free cash flow in the twelve months to 30 June 2026: −$82.4M.

  • Shares outstanding: 158.6M.

  • Trailing P/E: −0.4×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Fractyl Health, Inc. employs 100 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

GUTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GUTSFractyl Health, Inc.$64.8M
30
PLRXPliant Therapeutics, Inc.$64.1M
67
GOSSGossamer Bio, Inc.$65.4M
50
HRTXHeron Therapeutics, Inc.$66.0M
45
ELOXEloxx Pharmaceuticals, Inc.$62.6M
12
HYFTMindWalk Holdings Corp.$62.6M
51
XBITXBiotech, Inc.$66.8M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fractyl Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GUTS news & analysis

Deadline Alert: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

GlobeNewsWire · 5 Oct 2026negative

Glancy Prongay Wolke & Rotter LLP reminded Fractyl Health, Inc. investors of the October 20, 2026 deadline to file a lead plaintiff motion in a securities fraud class action. The lawsuit covers those who acquired GUTS securities between January 13, 2025 and January 29, 2026.

Why it matters — A GUTS watcher would want to track the pending securities fraud class action and its upcoming lead plaintiff deadline, as it introduces legal risk for the company.

Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th

GlobeNewsWire · 1 Oct 2026negative

Bragar Eagel & Squire, P.C. is urging Fractyl Health stockholders with large losses to contact the firm before October 20th to discuss their legal rights. The notice appears directed at investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026.

Why it matters — The law firm's outreach signals potential legal action tied to Fractyl's securities, which GUTS watchers would follow closely given possible shareholder litigation implications.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS

PRNewsWire · 30 Sept 2026negative

A law firm has reminded Fractyl Health shareholders of a lead plaintiff deadline of October 20, 2026 in connection with a lawsuit against the company. Two named officers — co-founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost roughly 74.86% of their value across two trading days.

Why it matters — GUTS watchers would care because the lawsuit and its lead plaintiff deadline concern allegations of overstated clinical data and significant share losses involving the company's CEO and former CFO.

FRACTYL HEALTH, INC. (GUTS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Fractyl Health, Inc. Investors of Upcoming Deadline

GlobeNewsWire · 30 Sept 2026negative

Bernstein Liebhard LLP issued a shareholder alert reminding Fractyl Health, Inc. investors of the October 20, 2026 deadline related to a securities fraud class action lawsuit commenced against the company. The law firm is notifying investors of the upcoming deadline.

Why it matters — GUTS watchers would note that the company is facing a securities fraud class action lawsuit with a defined investor deadline, which may be of legal and reputational concern.

Robbins LLP is Investigating Allegations that Fractyl Health, Inc. Misled Investors Regarding the Viability and Efficacy of its Revita DMR System

Newsfile Corp · 30 Sept 2026negative

Robbins LLP announced that a class action was filed against Fractyl Health, Inc. on behalf of those who acquired GUTS securities between January 13, 2025 and January 29, 2026. The firm is investigating allegations that Fractyl misled investors regarding the viability and efficacy of its Revita DMR system.

Why it matters — A securities class action and law firm investigation concerning potential investor misinformation about the company's Revita DMR system introduces legal and reputational risk for Fractyl Health.

FAQ

Frequently asked questions about GUTS stock

What is the GUTS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Fractyl Health, Inc. have a median 12-month price target of $5.1, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GUTS stock a buy right now?

Of the 7 analysts covering Fractyl Health, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fractyl Health, Inc. 30 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GUTS?

As at 3 Oct 2026, Fractyl Health, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).

Will GUTS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +4.5% from the last close, and Ticker Nerd's factor model ranks Fractyl Health, Inc. 30 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GUTS stock forecast for 2030?

No analyst covering Fractyl Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GUTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.

What does Fractyl Health, Inc. do?

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for obesity and type 2 diabetes.

What is the latest news on GUTS?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Deadline Alert: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit". Glancy Prongay Wolke & Rotter LLP reminded Fractyl Health, Inc. investors of the October 20, 2026 deadline to file a lead plaintiff motion in a securities fraud class action. The lawsuit covers those who acquired GUTS securities between January 13, 2025 and January 29, 2026.

Company

About Fractyl Health, Inc.

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for obesity and type 2 diabetes. Its current work centers on approaches that address the root causes of metabolic disease rather than only managing symptoms, with a primary emphasis on gut-based therapies. The company’s lead product candidate, Revita, is an investigational outpatient procedural therapy designed to remodel dysfunctional duodenal tissue and improve metabolic signaling. Fractyl Health is also developing Rejuva, a pancreatic gene therapy platform aimed at supporting longer-term metabolic control. Based in Burlington, Massachusetts, Fractyl Health operates in the healthcare and biotechnology space, where it is working on device- and therapy-based solutions for serious chronic metabolic conditions.

CEO Dr. Harith Rajagopalan M.D., Ph.D. · 100 employees · United States · https://fractyl.com